van der Heijde, Désirée https://orcid.org/0000-0002-5781-158X
Gensler, Lianne S
Deodhar, Atul
Baraliakos, Xenofon https://orcid.org/0000-0002-9475-9362
Poddubnyy, Denis https://orcid.org/0000-0002-4537-6015
Kivitz, Alan
Farmer, Mary Katherine
Baeten, Dominique
Goldammer, Nadine
Coarse, Jason
Oortgiesen, Marga
Dougados, Maxime
Clinical trials referenced in this document:
Documents that mention this clinical trial
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2025-006174
POS0919 BIMEKIZUMAB SHOWS SUSTAINED LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1840
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-004202
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study (Results)
https://doi.org/10.1136/annrheumdis-2020-216980
OP0231 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.6607
Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension
https://doi.org/10.1136/rmdopen-2024-005081
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2024-005026
POS0226 BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.156
POS0938 MAINTENANCE OF RESPONSE TO BIMEKIZUMAB OVER 3 YEARS OF TREATMENT IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POST HOC ANALYSES FROM THE BE AGILE STUDY AND ITS OPEN-LABEL EXTENSION
https://doi.org/10.1136/annrheumdis-2022-eular.2138
LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2018-eular.7889
POS0215 LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION
https://doi.org/10.1136/annrheumdis-2024-eular.2196
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
https://doi.org/10.1136/ard-2024-225933
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
OP0105 EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.323
Documents that mention this clinical trial
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2025-005969
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2025-006174
POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.833
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
https://doi.org/10.1136/ard-2022-223595
AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.2758
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-004202
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
https://doi.org/10.1136/ard-2023-224803
POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.836
POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.2416
POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2292
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2020-216980
POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.1996
POS0805 SUSTAINED IMPROVEMENTS WITH BIMEKIZUMAB IN PATIENT-REPORTED SYMPTOMS OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2197
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
https://doi.org/10.1136/rmdopen-2023-004040
POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.831
POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1562
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2024-005026
POS0246 BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.786
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
https://doi.org/10.1136/ard-2024-225933
AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.760
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702
POS0058 IMPACT OF BIMEKIZUMAB ON MRI INFLAMMATORY AND STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS AND POST HOC ANALYSES FROM THE BE MOBILE 1 AND 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.4903
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2025-006013
Documents that mention this clinical trial
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2025-005969
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2025-006174
POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.833
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
https://doi.org/10.1136/ard-2022-223595
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-004202
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
https://doi.org/10.1136/ard-2023-224803
POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.836
POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2292
LBA0003 MINIMAL SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS OVER 2 YEARS OF BIMEKIZUMAB TREATMENT: RESULTS FROM A PHASE 3 OPEN-LABEL EXTENSION STUDY
https://doi.org/10.1136/annrheumdis-2024-eular.lba62
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2020-216980
POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.1996
POS0805 SUSTAINED IMPROVEMENTS WITH BIMEKIZUMAB IN PATIENT-REPORTED SYMPTOMS OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2197
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
https://doi.org/10.1136/rmdopen-2023-004040
POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.831
POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1562
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2024-005026
OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.2441
POS0246 BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.786
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
https://doi.org/10.1136/ard-2024-225933
AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.760
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702
Axial spondyloarthritis: new advances in diagnosis and management
https://doi.org/10.1136/bmj.m4447
POS0058 IMPACT OF BIMEKIZUMAB ON MRI INFLAMMATORY AND STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS AND POST HOC ANALYSES FROM THE BE MOBILE 1 AND 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.4903
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2025-006013
Documents that mention this clinical trial
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2025-006174
POS0919 BIMEKIZUMAB SHOWS SUSTAINED LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1840
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-004202
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study (Results)
https://doi.org/10.1136/annrheumdis-2020-216980
OP0231 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.6607
Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension
https://doi.org/10.1136/rmdopen-2024-005081
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2024-005026
POS0226 BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.156
POS0938 MAINTENANCE OF RESPONSE TO BIMEKIZUMAB OVER 3 YEARS OF TREATMENT IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POST HOC ANALYSES FROM THE BE AGILE STUDY AND ITS OPEN-LABEL EXTENSION
https://doi.org/10.1136/annrheumdis-2022-eular.2138
LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2018-eular.7889
POS0215 LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION
https://doi.org/10.1136/annrheumdis-2024-eular.2196
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
https://doi.org/10.1136/ard-2024-225933
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
OP0105 EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.323
This article is maintained by: Elsevier
Article Title: Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
Journal Title: Annals of the Rheumatic Diseases
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/annrheumdis-2020-216980
Content Type: article
Copyright: Copyright © 2020 © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.